Federal Research Center for Virology and Microbiology (FRCVM), Petushki Area, Vladimir Region, 601125 Volginsky, Russia.
Viruses. 2022 Jul 26;14(8):1630. doi: 10.3390/v14081630.
The African swine fever virus (ASFV) is the cause of a recent pandemic that is threatening the global pig industry. The virus infects domestic and wild pigs and manifests with a variety of clinical symptoms, depending on the strain. No commercial vaccine is currently available to protect animals from this virus, but some attenuated and recombinant live vaccine candidates might be effective against the disease. This article describes the immunobiological characteristics of one such candidate-the laboratory-attenuated ASFV strain, Katanga-350-which belongs to genotype I. In this study, we assessed clinical signs and post-mortem changes, the levels of viremia and the presence of viral DNA caused by injection of ASF virus strains Katanga-350, Lisbon-57, and Stavropol 08/01. Intramuscular injection of this strain protected 80% of pigs from a virulent strain of the same genotype and seroimmunotype (Lisbon-57). At least 50% of the surviving pigs received protection from subsequent intramuscular infection with a heterologous (genotype II, seroimmunotype VIII) virulent strain (Stavropol 08/01). Virus-specific antibodies were detectable in serum and saliva samples between 8-78 days after the first inoculation of the Katanga-350 strain (the observational period). The results suggested that this strain could serve as a basis for the development of a recombinant vaccine against ASF viruses belonging to seroimmunotype I.
非洲猪瘟病毒（ASFV）是最近一次威胁全球养猪业的大流行的病原体。该病毒感染家猪和野猪，并表现出多种临床症状，具体取决于毒株。目前尚无商业疫苗可用于保护动物免受这种病毒的侵害，但一些减毒和重组活疫苗候选物可能对该疾病有效。本文描述了其中一种候选疫苗——实验室减毒 ASFV 株 Katanga-350 的免疫生物学特性，该毒株属于基因型 I。在这项研究中，我们评估了注射 ASFV 毒株 Katanga-350、Lisbon-57 和 Stavropol 08/01 后引起的临床症状和死后变化、病毒血症水平以及病毒 DNA 的存在。该菌株肌肉内注射可保护 80%的猪免受相同基因型和血清型（Lisbon-57）的强毒株感染。至少有 50%的幸存猪在随后的肌肉内感染异源（基因型 II，血清型 VIII）强毒株（Stavropol 08/01）时受到保护。在第一次接种 Katanga-350 株后的 8-78 天内，血清和唾液样本中可检测到病毒特异性抗体（观察期）。结果表明，该菌株可作为开发针对血清型 I 的 ASFV 重组疫苗的基础。
